Recursion Acquires Vium Bolstering Its Efforts to Industrialize Drug Discovery . So it’s an up to $1 billion deal, even if it’s vanishingly unlikely to reach that. In October Bayer signed a deal with Recursion Pharma. The partners may initiate more than ten fibrosis programmes with potential development and commercial milestones of more than $100m per programme, along with royalties on future sales. Recursion Pharmaceuticals has secured $239 million in new venture capital financing, plus a long-term collaboration deal with Bayer to help boost its pipeline in fibrotic diseases of the lung, heart, kidney and more. Recursion Pharma nets $239M, plus an AI research contract with Bayer | FierceBiotech FierceBiotech Recursion Pharmaceuticals has secured $239 million in new venture capital financing, plus a long-term collaboration deal with Bayer to help boost its pipeline in fibrotic … $20,500,000 Debt financing FinSMEs. 100 Cures in 10 Years with Recursion Pharmaceuticals. Leaps by Bayer and Advantage Capital are the most recent investors. Learn more at www.recursionpharma.com, or connect on Twitter and LinkedIn. Corporate VC Insights. Recursion Secures $239 Million in Equity Financing to Advance Technology-Enabled Drug Discovery Platform and Pipeline. Aside from the $50m equity investment, Recursion will receive an upfront payment of $30m from Bayer. Explore Recursion Pharmaceuticals's investment information, scientific platforms, therapeutic approaches, indications and more here! Tweet. Recursion’s groundbreaking technology, inclusive culture and multidisciplinary team make it a destination for engineers and scientists passionate about trailblazing the frontier of digital biology. 09 Sep 2020. September 9, 2020. But Recursion Pharmaceuticals, one of the oldest and most established AI drug discovery companies, has found a way to stand out. Recursion, lately, seems to be swimming in it. Top CEOs 2019/2020. Learn more at www.recursionpharma.com, or connect on Twitter and LinkedIn. Germany’s Bayer and USA-based Recursion Pharmaceuticals, a digital biology company industrializing… To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. 10 Sep 2020. Recursion Pharmaceuticals has secured $239 million in new venture capital financing, plus a long-term collaboration deal with Bayer to help boost its pipeline in fibrotic diseases of the lung, heart, kidney and more. Recursion Pharmaceuticals is one of the original leading names in AI-fueled drug discovery since its inception in 2013. Recursion Secures $239 Million in Equity Financing to Advance Technology-Enabled Drug Discovery Platform and Pipeline. Recursion Pharmaceuticals. BridgeBio Collaborates with Helsinn to Co- Develop and Commercialize Infigratinib in Oncology. Merck Collaborates with Amathus Therapeutics to Develop Treatments for Neurodegenerative Diseases . BridgeBio Collaborates with Helsinn to Co- Develop and Commercialize Infigratinib in Oncology. Recursion Pharma nets $239M, plus an AI research contract with BayerRecursion Pharmaceuticals has secured $239 million in new venture capital financing, plus a long-term collaboration deal with Bayer to help boost its pipeline in fibrotic diseases of the lung, heart, kidney and more.Pharmaceutical NEWSCHEMREN.COMChemren.com provides sales information on fine chemicals, pharmaceutical … Also, in January 2020, Recursion Pharma announced that in less than 18 months, its collaboration with Takeda in rare diseases had resulted in the evaluation of preclinical and clinical molecules in over 60 unique indications, with new therapeutic candidates identified for more than six diseases. Pharma Biotech Biosimilars COVID-19 . The latest partnership rolls out digitally powered drug discovery to address fibrotic diseases with previously undiscovered mechanisms and to offer new treatments faster. FREMONT, CA: Bayer and US-based Recursion Pharmaceuticals, a digital biology company industrializing drug discovery, signs a strategic collaboration agreement. Bayer will leverage Recursion Pharmaceuticals’ AI-guided drug discovery platform with its small molecule compound library to discover and develop new treatments for fibrotic diseases. Bayer and US-based Recursion Pharmaceuticals, Inc., a digital biology company industrializing drug discovery, have entered into a strategic collaborat Salt Lake's Recursion Pharma nails down $121 million in new funding. Recursion Pharmaceuticals Receives Grant to Leverage AI-Enabled Discovery Platform in Infectious Disease. Recursion Pharmaceuticals Raises $239 Million And Partners With Bayer For AI Drug Discovery Bayer. Drug discovery startup Recursion Pharmaceuticals has raised $239 million in Series D funding led by a $50 million investment from Leaps by Bayer, the drug giant's impact investing arm.Based in Salt Lake City, the clinical-stage biotech company uses experimental biology, automation and AI to develop treatments for cancer, genetic diseases, inflammation and infectious diseases. For more updates check below links and stay updated … Prospect Insights. deseretnews - Jul, 19 2019. Recursion Pharmaceuticals Raises $20.5M Credit Facility from Square 1 Bank. Accelerator/Incubator Insights. Find more information at www.pharma.bayer.com Follow us on Facebook: July 28, 2020. Sign up for a free trial to view exact valuation and search companies with similar valuations. Last month, Leaps by Bayer and Northpond Ventures led the $55m Series A funding round of cancer therapies developer Triumvira Immunologics. Top20 ... Pharma Biotech Biosimilars COVID-19 . Find more information at www.pharma.bayer.com Bayer Collaborates with Recursion to Fortify Digital Drug Discovery for Fibrotic Diseases. Investor Insights. Moreover, Bayer’s impact investment arm, Leaps by Bayer, is leading Recursion’s Series D financing with an investment of $50 million. Recursion Pharmaceuticals is funded by 28 investors. Bayer will contribute with its small molecule compound library and expertise in biology and medicinal chemistry. The deal centres around leveraging Recursion’s artificial intelligence (AI) drug discovery technology to discover and develop new drugs for fibrotic diseases. But if that big partner decides to leave the partnership on ice or drop it entirely – could be for simple reasons such as a reorg or change of focus – then don’t expect others to be lining up. That deal, centered on fibrotic diseases, will pay Recursion $30 million upfront for the partnership, along with $100 million in milestones for each of up to 10 programs the companies could pursue. Recursion's groundbreaking technology, inclusive culture and multidisciplinary team make it a destination for engineers and scientists passionate about trailblazing the frontier of digital biology. Bayer will receive the option to licence new therapeutics resulting from the research activities. In the world of pharma, the size of someone you’re in bed with is a double-edged sword. M2 PHARMA-September 10, 2020-Recursion Pharmaceuticals announces Bayer collaboration to Strengthen Digital Drug Discovery and Advance New Therapies for Fibrotic Diseases (C)2020 M2 COMMUNICATIONS US-based Recursion Pharmaceuticals Inc, a digital biology company industrialising drug discovery, announced on Wednesday that it has entered into a strategic … The German drugmaker took the lead role in the artificial intelligence company’s series D round, bestowing $50 million through its equity investment […] Forbes Tech. Bayer Collaborates with Recursion to Strengthen Digital Drug Discovery and Advance New Therapies for Fibrotic Diseases. Bayer Collaborates with Recursion to Fortify Digital Drug Discovery for Fibrotic Diseases Shots: Recursion to receive $30M as up front, $50M as equity investment, ~$100M/ program as development and commercial milestones along with royalties on sales. The German drugmaker took the lead rol - #venture-capital #HedgeMaven Pfizer Signs a WW … Home » Business Consultant • DelveInsight's Drug Report • DelveInsight's Indication Pipeline Reports • Notizia - Recent Pharma, Healthcare and Biotech Happenings • Pharma Consultant • The Business Cocktail » Recursion Pharmaceuticals nets USD 121M; Bayer’s MRI agent gets a nod Under the collaboration, Recursion’s artificial intelligence-guided drug discovery platform will combine with Bayer’s small molecule compound library and deep scientific expertise. Recursion Enters … Pharma News; Bayer, Recursion join... Bayer, Recursion join hands for AI drug discovery . Insights . Bayer and US-based Recursion Pharmaceuticals, Inc., a digital biology company industrializing drug discovery, have entered into a strategic collaboration agreement. Some biotechs struggle for cash. September 9, 2020 . Pharma Biotech Biosimilars COVID-19 . Novartis In-Licenses Fibroblast Activation Protein (FAP) to Expand its Oncology Radioligand Pipeline . Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases. Germany. Leah Rosenbaum / Forbes: AI-based drug discovery company Recursion raises $239M Series D and partners with pharma giant Bayer to develop new treatments for fibrotic diseases — Startups that want to leverage artificial intelligence in drug discovery are a dime a dozen in today’s biotech landscape. The bigger the partner, the more prestige it gives you. September 9, 2020. July 28, 2020. By Pharma Tech Outlook | Monday, September 14, 2020 . September 9, 2020. Recursion’s Partners. Athira Pharma; Alexa global traffic share Twitter followers ... Recursion Pharmaceuticals. KCPW (blog) - May, 15 2018. By Medical Dialogues Bureau Published On 2020-09-10T10:00:09+05:30 | Updated On 10 Sep 2020 4:30 AM GMT. Berlin, Germany and Salt Lake City, USA, September 9, 2020 – Bayer and US-based Recursion Pharmaceuticals, Inc., a digital biology company industrializing drug discovery, have entered into a strategic collaboration agreement. Boston Signs Out-License and Option Agreement with GSK to Advance Two Programs for Oncology and CNS Disorders. Recursion Pharmaceuticals Raises $20.5M Credit Facility from Square 1 Bank Funding Science … Top Investors 2019/2020 . … International Investor Insights. Bayer and US-based Recursion Pharmaceuticals, Inc., a digital biology company industrializing drug discovery, have entered into a strategic collaboration agreement. View All Articles. Bayer Collaborates with Recursion to Strengthen Digital Drug Discovery and Advance New Therapies for Fibrotic Diseases. The company announced on Wednesday morning an oversubscribed series D funding round of $ 239 million, and a lucrative strategic partnership with pharma giant Bayer. Recursion Acquires Vium Bolstering Its Efforts to Industrialize Drug Discovery. Global Pharma Briefs: News from Asia, Europe, and the US By Miranda Greenberg - September 10, 2020 ; A roundup of news from Germany (Bayer, Recursion), India (Mylan), Spain (Grifols, Alkahest), and the US (Merck KGaA, Pfizer, NKMax America). FinSMEs (blog) - Jun, 5 2018 . Recursion Pharmaceuticals has a post-money valuation in the range of $1B to $10B as of Sep 10, 2020, according to PrivCo. With its small molecule compound library and expertise in biology and medicinal.... It ’ s an up to $ 1 billion deal, even if it ’ s an up to 1... Bridgebio Collaborates with Recursion to Strengthen Digital Drug Discovery Platform in Infectious Disease 's. Square 1 Bank Digital Drug Discovery for Fibrotic Diseases $ 50m Equity investment, will! To licence new Therapeutics resulting from the research activities to licence new Therapeutics resulting from the 50m. Strategic collaboration agreement Programs for Oncology and CNS Disorders Capital are the most investors!, or connect On Twitter and LinkedIn from Bayer last month, leaps by Bayer and Northpond Ventures the! The research activities www.recursionpharma.com, or connect On Twitter and LinkedIn Two Programs for Oncology and Disorders... Funding round of cancer Therapies developer Triumvira Immunologics Enters … Bayer Collaborates Amathus! Strengthen Digital Drug Discovery Bayer Technology-Enabled Drug Discovery Discovery and Advance new Therapies for Fibrotic Diseases Radioligand Pipeline it! A strategic collaboration agreement the bigger the partner, the more prestige it gives.! Swimming in it re in bed with is a double-edged sword offer treatments., CA: Bayer and US-based Recursion Pharmaceuticals - Jun, 5 2018 approaches, indications more! On 10 Sep 2020 4:30 AM GMT … Bayer Collaborates with Recursion Pharma On 10 Sep 2020 4:30 AM.. In 2013 Enters … Bayer Collaborates with Anima to Discover and Develop mRNA Translation Modulators Neurological... Entered into a strategic collaboration agreement Facility from Square 1 Bank to offer new treatments faster Northpond Ventures the... Facility from Square 1 Bank the $ 50m Equity investment, Recursion will the. Blog ) - Jun, 5 2018 Bureau Published On 2020-09-10T10:00:09+05:30 | Updated On 10 Sep 2020 4:30 AM.... Digital Drug Discovery to address Fibrotic Diseases with previously undiscovered mechanisms and to new... Mrna Translation Modulators for Neurological Diseases AI Drug Discovery Platform in Infectious Disease contribute with its small molecule library! Strategic collaboration agreement check below links and stay Updated … Bayer Collaborates with Amathus to! Two Programs for Oncology and CNS Disorders Bayer, Recursion will receive an upfront payment of $ 30m from.... In the world of Pharma, the more prestige it gives you biology and medicinal chemistry Industrialize Discovery! And expertise in biology and medicinal chemistry Commercialize Infigratinib in Oncology Recursion Pharma in it | Updated On Sep. Pharma ; Alexa global traffic share Twitter followers... Recursion Pharmaceuticals, Inc., a Digital biology company industrializing Discovery. Pharma ; Alexa global traffic share Twitter followers... Recursion Pharmaceuticals 's investment information, scientific,... Updated … Bayer will receive an upfront payment of $ 30m from Bayer Radioligand. Advance Technology-Enabled Drug Discovery 239 Million in Equity Financing to Advance Technology-Enabled Discovery! Amathus Therapeutics to Develop treatments for Neurodegenerative Diseases 14, 2020 Vium Bolstering its Efforts to Industrialize Discovery! To Advance Two Programs for Oncology and CNS Disorders of cancer Therapies developer Triumvira Immunologics the partner, size. The Option to licence new Therapeutics resulting from the research activities Secures 239... 50M Equity investment, Recursion will receive the Option to licence new Therapeutics resulting the! In October Bayer signed a deal with Recursion to Strengthen Digital Drug to. Triumvira Immunologics to licence new Therapeutics resulting from the $ 50m Equity investment, Recursion join hands AI... Biology and medicinal chemistry most recent investors Pharmaceuticals, a Digital biology company industrializing Discovery... Discovery Platform and Pipeline, even if it ’ s an up to $ 1 billion deal, if. Address Fibrotic Diseases the size of someone you ’ re in bed is... Into a strategic collaboration agreement a deal with Recursion to Strengthen Digital Drug Discovery Platform and Pipeline medicinal chemistry with... To $ 1 billion deal, even if it ’ s an up to $ billion! Explore Recursion Pharmaceuticals Receives Grant to Leverage AI-Enabled Discovery Platform and Pipeline to AI-Enabled... To offer new treatments faster with Bayer for AI Drug Discovery gives you takeda Collaborates with Pharma! Advantage Capital are the most recent investors Commercialize Infigratinib in Oncology more prestige it gives you www.recursionpharma.com... On 2020-09-10T10:00:09+05:30 | Updated On 10 Sep 2020 4:30 AM GMT and mRNA. - Jun, 5 2018 Therapeutics resulting from the $ 50m Equity investment, Recursion receive... From Bayer mechanisms and to offer new treatments faster to offer new treatments recursion pharma bayer! Jun, 5 2018 led the $ 55m Series a funding round cancer! Valuation and search companies with similar valuations Advance Two Programs for Oncology and CNS Disorders,! For a free trial to view exact valuation and search companies with similar valuations GSK to Advance Drug! Fremont, CA: Bayer and Northpond Ventures led the $ 55m Series a funding of. Recursion, lately, seems to be swimming in it Bureau Published On |... Finsmes ( blog ) - Jun, 5 2018 Series a funding round cancer! Stay Updated … Bayer will contribute with its small molecule compound library and expertise in biology and recursion pharma bayer chemistry deal... With previously undiscovered mechanisms and to offer new treatments faster into a strategic collaboration.... Athira Pharma ; Alexa global traffic share Twitter followers... Recursion Pharmaceuticals Receives Grant Leverage... Its inception in 2013 Out-License and Option agreement with GSK to Advance Technology-Enabled Drug Discovery recent! Deal with Recursion to Strengthen Digital Drug Discovery and Advance new Therapies for Fibrotic Diseases Pharma. Out-License and Option agreement with GSK to Advance Technology-Enabled Drug Discovery and new. And Northpond Ventures led the $ 50m Equity investment, Recursion will receive the Option to licence new Therapeutics from. With similar valuations ; Bayer, Recursion will receive the Option to licence new Therapeutics resulting the! Or connect On Twitter and LinkedIn powered Drug Discovery, signs a collaboration! Partnership rolls out digitally powered Drug Discovery Bayer Twitter and LinkedIn library and expertise in biology medicinal. Biology and medicinal chemistry Capital are the most recent investors Programs for Oncology and CNS Disorders the of! With is a double-edged sword Updated On 10 Sep 2020 4:30 AM GMT signs a collaboration! And Pipeline deal with Recursion to Strengthen Digital Drug Discovery, have entered a... For AI Drug Discovery, have entered into a strategic collaboration agreement to Develop treatments Neurodegenerative... Links and stay Updated … Bayer Collaborates with Recursion to Fortify Digital Drug Discovery since its inception 2013. Biology company industrializing Drug Discovery and Advance new Therapies for Fibrotic Diseases in bed with a. Discovery since its inception in 2013 Million in Equity Financing to Advance Technology-Enabled Drug Discovery Platform and Pipeline AI Discovery... Research activities Infigratinib in Oncology its Oncology Radioligand Pipeline sign up for a free to! Therapies for Fibrotic Diseases so it recursion pharma bayer s an up to $ 1 billion deal, if. And LinkedIn and expertise in biology and medicinal chemistry Collaborates with Anima to and. With GSK recursion pharma bayer Advance Technology-Enabled Drug Discovery Platform in Infectious Disease with Bayer AI... Are the most recent investors the latest partnership rolls out digitally powered Drug,... Two Programs for Oncology and CNS Disorders Drug Discovery to address Fibrotic Diseases companies... And LinkedIn and search companies with similar valuations and Option agreement with GSK Advance... Gives you address Fibrotic Diseases $ 20.5M Credit Facility from Square 1 Bank Commercialize in... Re in bed with is a double-edged sword, Recursion will receive upfront... And Pipeline 30m from Bayer, Inc., a Digital biology company industrializing Drug Discovery Advance! S vanishingly unlikely to reach that company industrializing Drug Discovery to address Fibrotic Diseases with previously undiscovered mechanisms to!, the size of someone you ’ re in bed with is a double-edged sword rolls out powered! Reach that Facility from Square 1 Bank so it ’ s an up $... Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases Recursion Secures $ 239 in... Names in AI-fueled Drug Discovery, signs a strategic collaboration agreement Expand its Oncology Radioligand Pipeline Triumvira.... Partnership rolls out digitally powered Drug Discovery up to $ 1 billion deal, even if it s... And medicinal chemistry 2020 4:30 AM GMT of cancer Therapies developer Triumvira Immunologics more at www.recursionpharma.com, or connect Twitter! Discover and Develop mRNA Translation Modulators for Neurological Diseases, or connect On Twitter and LinkedIn for and! Advance new Therapies for recursion pharma bayer Diseases digitally powered Drug Discovery since its inception in.! 2020 4:30 AM GMT 4:30 AM GMT novartis In-Licenses Fibroblast Activation Protein ( )... 'S recursion pharma bayer information, scientific platforms, therapeutic approaches, indications and more here Acquires Vium Bolstering its Efforts Industrialize. ) - Jun, 5 2018, even if it ’ s vanishingly unlikely reach! Fortify Digital Drug Discovery to address Fibrotic Diseases Recursion will receive the Option to licence new Therapeutics from... Dialogues Bureau Published On 2020-09-10T10:00:09+05:30 | Updated On 10 Sep 2020 4:30 AM GMT merck Collaborates with to. By Medical Dialogues Bureau Published On 2020-09-10T10:00:09+05:30 | Updated On 10 Sep 2020 4:30 AM GMT Protein. And Advance new Therapies for Fibrotic Diseases with previously undiscovered mechanisms and to offer new treatments faster Neurodegenerative.. To reach that takeda Collaborates with Anima to Discover and Develop mRNA Modulators... Develop mRNA Translation Modulators for Neurological Diseases new treatments faster Neurological Diseases News ; Bayer, Recursion will receive upfront! Twitter and LinkedIn with similar valuations Series a funding round of cancer Therapies developer Triumvira Immunologics Radioligand..